GlassScriptPhysician profile
Morgan D Burks
NPI 1336713494
$1,797.15
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $231 · 2023: $985 · 2024: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $322.29 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $281.14 | 2022-2024 | |
| Pfizer INC. | $138.59 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $112.90 | 2023-2024 | Breztri, Evusheld, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $106.94 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $102.79 | 2022-2023 | Quviviq |
| Harmony Biosciences LLC | $91.31 | 2023-2024 | Wakix |
| Glaxosmithkline, LLC. | $80.72 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $68.27 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $61.93 | 2023 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.35 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.82 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $47.87 | 2022-2024 | Saxenda, Wegovy, Rybelsus |
| Phathom Pharmaceuticals, INC. | $42.91 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $36.48 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $30.88 | 2024 | Opsumit, Uptravi |
| Inari Medical, INC. | $29.88 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.33 | 2022-2023 | Stiolto Respimat |
| Eisai INC. | $27.05 | 2024 | |
| Dexcom, INC. | $24.88 | 2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $23.96 | 2023 | Tymlos |
| Astellas Pharma US INC | $15.11 | 2023 | Veozah |
| Amgen INC. | $13.75 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Burks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.